1. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing- remitting MS. J Neurosci Nurs. 2006;38:167-171. [PubMed]

2. Namey NA. Promoting adherence to complex protocols. In: Halper J, ed. Advanced Concepts in Multiple Sclerosis Nursing Care. New York: Demos Medical; 2001. 

3. Compston A, Ebers G, Lassmann H, et al. McAlpine’s Multiple Sclerosis, 3rd ed. New York: Churchill Livingstone; 1999. 

4. Moore LA, Kaufman MD, Algozzine R, et al. Adherence to therapy: using an evidence-based protocol. Rehabil Nurs. 2007;32:227-232. [PubMed]

5. Ball NJ, Cowan BJ, Moore GR, Hashimoto SA. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing–remitting MS. A report of two cases. J Cutan Pathol. 2008;35:407-410. [PubMed]

6. Halper J, Harris C, Machler B. Managing injection site reactions in patients with MS. Mult Scler Counsel Points. 2005;1:1-10. 

7. O’Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11:46-50. [PubMed]

8. Twork S, Nippert I, Scherer P, et al. Immunomodulating drugs in MS: compliance, satisfaction, and adverse effects evaluation in a German population. Curr Med Res Opin. 2007;23:1209-1215. [PubMed]

9. Goldman Consensus Group. Goldman consensus statement on depression in MS. Mult Scler. 2005;11;328-337. [PubMed]

10. Mohr DC, Goodkin DE. Treatment of depression in MS: review and metaanalysis. Clin Psychol Sci Pract. 1999;6:1-9.

11. Feinstein A, O’Connor P, Feinstein K. MS, interferon beta-1b and depression: a prospective investigation. J Neurol. 2002;24:815-820. [PubMed]

12. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for MS. Arch Neurol. 1997;54:531-533. [PubMed]

13. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to immunomodulatory drugs for MS: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17:565-576. [PubMed]

14. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.

15. Cohen BA, Rieckmann P. Emerging oral therapies for MS. Int J Clin Pract. 2007;61:1922-1930. [PubMed]

16. O’Connor PW, Li D, Freedman MS, et al. A phase II study of safety and efficacy of teriflunomide in MS with relapses. Neurology. 2006;66:894-900. [PubMed]

17. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting MS: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-2092. [PubMed]

18. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing MS. N Engl J Med. 2006;355;1124-1140. [PubMed]

19. Romine JS, Sipe JC, Koziol JA, et al. Double-blind, placebo-controlled, randomized trial of cladribine in RRMS. Proc Assoc Am Physicians. 1999;111:35-44. [PubMed]

20. Kappos L, Miller DH, MacManus DG, et al. BG00012, a novel fumarate is effective in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006;12:S85.

21. Garren H, Robinson WH, Krasulova E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for MS. Ann Neurol. 2008;63:611-620. [PubMed]

22. Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II–defined cohort of patients with progressive multiple sclerosis: results of a 24-month doubleblind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13:887-895. [PubMed]

23. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-1249. [PubMed]

24. Comi G, Filippi M. Treatment with glatiramer acetate delays conversion to clinically definite MS in patients with clinically isolated syndromes. Presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago, 2008.

25. Arnold D, Bar-Or A, Freedman M, et al. Reductions in Gd-enhancing lesions observed with glatiramer acetate following brief low-dose course of mitoxantrone in patients with relapsing–remitting MS are paralleled by favorable effects on MRI markers of disease burden and black hole evolution. Neurology. 2007;68(suppl):A281.

26. Edan G, Comi G, Lebrun D, et al. The French-Italian mitoxantrone-interferon- beta trial: a 3-year randomised study. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic. 2007 

27. CombiRx. A Multi-center, double-Blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in patients with relapsing-remitting multiple sclerosis. Overview in: ClinicalTrials.gov.

28. Simsarian JP, Pardo G, Barbarash O, et al. Safety and immunogenicity of Rebif New Formulation, a new subcutaneous formulation of interferon beta- 1a 44 mcg three times weekly: 1-year results of a phase IIIb study in patients with relapsing–remitting MS. Neurology. 2007;68(suppl):A274.

29. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of MS. Ann Neurol. 2007;62:452-457. [PubMed]

30. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin. N Engl J Med. 2000;342;665. [PubMed]